Import Cancer Medications

Import Cancer Medicine

Import Cancer Medicine

Looking for FDA approved cancer medicines? We help you import into India.

Medullary thyroid cancer

Company: Ipsen

COMETRIQ® (cabozantinib) is indicated for the treatment of patients with progressive, metastatic medullary thyroid cancer (MTC) … COMETRIQ® (cabozantinib) has been shown to inhibit the activity of MET; VEGFR-1, -2, and -3; RET; and other receptor tyrosine kinases, in vitro

Tablets: 140mg (112 tabs)

Caprelsa

Company: Sanofi

CAPRELSA is a prescription medication used to treat patients with medullary thyroid cancer (MTC) that cannot be removed by surgery or that has spread to other parts of the body, and in which the tumors are growing or causing symptoms. This type of MTC is typically called advanced medullary thyroid cancer (aMTC).

Tablets: 100 mg (30 tabs), 300 mg (30 tabs)

Non-small cell lung cancer

Company: Takeda (Germany)

Alunbrig is a cancer medicine that is used to treat adults with a type of lung cancer called non-small cell lung cancer (NSCLC) who have been treated before with a cancer medicine called crizotinib.

Alunbrig is used on its own and only if the NSCLC is ‘ALK-positive’, which means that the cancer cells have certain changes affecting the gene that makes a protein called ALK (anaplastic lymphoma kinase).

Tablets: 30mg (28 tabs), 90mg (28 tabs), 180mg (28mg)

Company: Novartis

For the treatment of unresectable or metastatic melanoma that is caused by a defect in a gene called BRAF. The cancer must be (BRAF)-positive as indicated by an FDA-approved test. MEKINIST is a kinase inhibitor indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test

Tablets: 0.5mg (30 tabs), 2mg (30 tabs)

Company: Lilly

Portrazza (necitumumab) is an epidermal growth factor receptor (EGFR) antagonist.
Portrazza is specifically indicated for use in combination with gemcitabine and cisplatin, for first-line treatment of patients with metastatic squamous non-small cell lung cancer.

800mg (1 vial) 

Company: Novartis

Tafinlar is the trade name for the generic chemotherapy drug dabrafenib. Tafinlar is a targeted therapy. It is an oral BRAF kinase inhibitor. For the treatment of unresectable or metastatic melanoma that is caused by a defect in a gene called BRAF. The cancer must be (BRAF)-positive as indicated by an FDA-approved test. Used in combination with trametinib (Mekinist®) for the treatment of metastatic non-small cell lung cancer (NSCLC). The cancer must be BRAF positive as indicated by an FDA-approved test.

Tablets: 50mg (120 caps), 75mg (120 caps)

Company: Hexal

Hycamtin is an anti-cancer (“antineoplastic” or “cytotoxic”) chemotherapy drug.  Hycamtin is classified as an “topoisomerase 1 inhibitor. This medicine is used to treat cancer of the ovaries when other treatments have failed. Hycamtin may also used in certain types of lung cancer (small cell lung cancer)

Tablets: 1 mg (10 caps), 1 mg (1 vial)

Multiple myeloma

Company: Takeda

Ixazomib is a targeted therapy. This medication is classified as a “proteasome inhibitor. Multiple myeloma, Ixazomib is used in combination with lenalidomide and dexamethasone in patients who have received at least one prior therapy

Tablets: NA 2,3 mg or 3 mg or 4 mg (3 caps)

Company: BMS

Elotuzumab is an anti-cancer (“antineoplastic” or “cytotoxic”) chemotherapy drug. This medication is classified as a “monoclonal antibody (anti SLAMF7)

Tablets: 300mg (1 vial),  400mg (1 vial)

Metastatic melanoma

Company: Novartis

For the treatment of unresectable or metastatic melanoma that is caused by a defect in a gene called BRAF. The cancer must be (BRAF)-positive as indicated by an FDA-approved test. MEKINIST is a kinase inhibitor indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test

Tablets: 0.5mg (30 tabs)

Company: Novartis

Tafinlar is the trade name for the generic chemotherapy drug dabrafenib. Tafinlar is a targeted therapy. It is an oral BRAF kinase inhibitor. For the treatment of unresectable or metastatic melanoma that is caused by a defect in a gene called BRAF. The cancer must be (BRAF)-positive as indicated by an FDA-approved test. Used in combination with trametinib (Mekinist®) for the treatment of metastatic non-small cell lung cancer (NSCLC). The cancer must be BRAF positive as indicated by an FDA-approved test.

Tablets: 50 mg (120 caps), 75 mg (120 caps)

Breast Cancer

Company: Novartis

Ribociclib is an anti-cancer kinase inhibitor. This medication is classified as a “cyclin-dependent kinase inhibitor.”

Tablets: 200 mg (120 caps), 75 mg (120 caps)

Company: AstraZeneca

Olaparib is a targeted therapy. It is poly (ADP-ribose) polymerase (PARP) inhibitor. Advanced ovarian cancer (with deleterious germline BRCA mutated (gBRCAm) as detected by an FDA-approved test) who have been treated with three or more prior lines of chemotherapy. HER2-negative metastatic breast cancer (with deleterious or suspected gBRCAm), who have been treated with chemotherapy.

Tablets: 50 mg (448 caps), 100 mg (112 tabs), 
150 mg (112 tabs)

Company: AstraZeneca

Olaparib is a targeted therapy. It is poly (ADP-ribose) polymerase (PARP) inhibitor. Advanced ovarian cancer (with deleterious germline BRCA mutated (gBRCAm) as detected by an FDA-approved test) who have been treated with three or more prior lines of chemotherapy. HER2-negative metastatic breast cancer (with deleterious or suspected gBRCAm), who have been treated with chemotherapy.

Tablets: 50 mg (448 caps), 100 mg (112 tabs), 
150 mg (112 tabs)

Company: Novartis

For the treatment of FLT3 positive acute myeloid leukemia and mastocytosis

Tablets: 25 mg (112 caps)

Company: Novartis

For the treatment of FLT3 positive acute myeloid leukemia and mastocytosis

Tablets: 25 mg (112 caps)

Leukemia

Company: Novartis

Midostaurin is a targeted anti-cancer therapy. This medication is classified as a tyrosine kinase inhibitor, more specifically a FLT3 inhibitor. Acute Myeloid Leukemia (AML) that is FLT3-positive
Mast Cell Leukemia (MCL)
Aggressive Systemic Mastocytosis (ASM)
Systemic Mastocytosis with Associated Hematological Neoplasm (SM-AHN)

Tablets: 25 mg (112 caps)

Company: Amgen

Blincyto ® is a monoclonal antibody. A bispecific T-cell engager” (BiTE) antibody. Blincyto ® is used in the treatment of acute lymphoblastic leukemia (ALL)

Tablets: 38,5 µg (1 vial)

Company: Abbvie

Venetoclax is an Antineoplastic Agent; BCL-2 Inhibitor. Indicated for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). In combination with azacitidine, or decitabine, or low-dose cytarabine to treat adults with newly-diagnosed acute myeloid leukemia (AML) who: are 75 years or older, or have other medical conditions that prevent the use of standard chemotherapy.

Tablets: 10 mg (14 tabs), 50mg (7 tabs), 100mg (14 tabs)

Company: Gilead

Zydelig® is a targeted therapy. It is an oral Phosphatidylinositol 3-kinase inhibitor. Chronic lymphocytic leukemia: Treatment of relapsed chronic lymphocytic leukemia (CLL) (in combination with rituximab) when rituximab alone is appropriate therapy due to other comorbidities. Follicular B-cell non-Hodgkin lymphoma: Treatment of relapsed follicular B-cell non-Hodgkin lymphoma after at least 2 prior systemic therapies. Small lymphocytic lymphoma: Treatment of relapsed small lymphocytic lymphoma (SLL) after at least 2 prior systemic therapies.

Tablets:  100mg or 150mg (60 tabs)

Company: Hexal

Nelarabine is a chemotherapy drug and is also known by its brand name, Atriance. It is a treatment for:  
T cell acute lymphoblastic leukaemia and T cell lymphoblastic lymphoma

Tablets: Infusion (6 x 50 ml)

Cutaneous T-cell lymphoma

Company: Takeda

Adcetris® is an anti-cancer (“”antineoplastic”” or “”cytotoxic””) chemotherapy drug. This medication is classified as an “”­­­­­­­­­antineoplastic agent and a monoclonal antibody”. 

  • Treatment of adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy.
  • Treatment of patients with Classical Hodgkin Lymphoma (cHL) at high risk of relapse or progression as post autologous hematopoietic stem cell transplantation (auto-HSCT) consolidation.
  • Treatment of patients with cHL after failure of auto-HSCT or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not candidates for auto-HSCT.
  • Treatment of patients with systemic anaplastic large cell lymphoma after failure of at least one prior multi-agent chemotherapy regimen.
  • Treatment of patient with primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy.”

Tablets: 50 mg (1 vials)

Company: Gilead

Tablets: 100 mg or 150 mg (60 tabs)

Ovarian Cancer

Company: AstraZeneca

Olaparib is a targeted therapy. It is poly (ADP-ribose) polymerase (PARP) inhibitor. Advanced ovarian cancer (with deleterious germline BRCA mutated (gBRCAm) as detected by an FDA-approved test) who have been treated with three or more prior lines of chemotherapy. HER2-negative metastatic breast cancer (with deleterious or suspected gBRCAm), who have been treated with chemotherapy.

Tablets: 50mg (448 caps), 100 mg (112 tabs), 150mg (112 tabs)

Company: Tesaro

Trifluridine/tipiricil is used to treat metastatic colorectal cancer in patients who have previously been treated with fluoropyrimidine, oxaliplatin, and irinotecan based chemotherapy, an anti-VEGF biological therapy, and an anti-EGFR therapy (if RAS wild type).
To treat metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma previously treated with at least two prior lines of chemotherapy that included fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy.

Tablets: 100 mg (56 tabs)/(84 tabs)

Pancreatic Cancer

Company: Servier

Irinotecan (liposomal) is an anti-cancer (“antineoplastic” or “cytotoxic”) chemotherapy drug. This medication is classified as a “Topoisomerase I Inhibitor.” Metastatic pancreatic cancer (in combination with flurouracil and leucovorin)

Tablets: 5mg / ml (1 x 10 ml)

Colorectal Cancer

Company: Servier

Tablets: 15mg / 6,14mg (20 tabs)/(60 tabs);
20mg / 8,19 mg (20 tabs)/( 60 tabs)

All

Company: Servier

Inotuzumab ozogamicin is a monoclonal antibody combined with an anti-cancer (“antineoplastic” or “cytotoxic”) chemotherapy drug. This medication is classified as an “Anti-CD22 monoclonal antibody and antineoplastic agent.

Tablets: 1mg / 1 vial

Chronic Myelogenous Leukemia

Company: Incyte

Tablets: 15mg (30 tabs)
30mg or 45mg (30 tabs)

Merkel Cell Carcinoma

Company: Merck

Avelumab is an anti-PD-L1 monoclonal antibody. Treatment of a specific type of skin cancer, metastatic Merkel cell carcinoma (MCC), in adults and children at least 12 years old.
Treatment of locally advanced or metastatic urinary system cancer.
In combination with axitinib for first-line treatment of patients with advanced renal cell carcinoma (RCC)

Tablets:20 mg/ml (10ml vial)

Marginal Zone Lymphoma​

Company: Janssen-Cillag

Imbruvica™ is a targeted therapy. Imbruvica™ inhibits the function of Bruton’s tyrosine kinase (BTK). Chronic graft-versus-host (cGVHD) disease after failure of one or more prior lines of systemic therapy.

  • Chronic lymphocytic leukemia (CLL) who have received at least one prior therapy.
  • Mantle cell lymphoma (MCL) who have received at least one prior therapy.
  • Marginal zone lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy.
  • Waldenstrom’s macroglobulinemia

Tablets: 140mg (28 tabs), 280mg (28 tabs), 420mg (28 tabs), 560mg (28 tabs)

Advanced or Metastatic Urothelial Carcinoma and Stage III Non-small Cell Lung Cancer

Durvalumab is an anti-cancer (“”antineoplastic””) drug. This medication is classified as an Anti-PD-L1 monoclonal antibody. Durvalumab is used to treat urothelial cancers that are locally advanced or metastatic in patients who have disease progression during or following platinum containing chemotherapy or who have disease progression within 12 months of neo-adjuvant or adjuvant treatment with platinum containing chemotherapy.
Durvalumab is used for patients with unresectable stage III non-small cell lung cancer (NSCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.

Tablets: 500 mg (1 vial)

Adults with relapsed or refractory B-cell precursor acute Lymphoblastic Leukemia

Company: Pfizer

Inotuzumab ozogamicin is a monoclonal antibody combined with an anti-cancer (“antineoplastic” or “cytotoxic”) chemotherapy drug. This medication is classified as an “Anti-CD22 monoclonal antibody and antineoplastic agent.

Tablets: 1mg/ml (1 vial)

Liver Cancer

Company: Bristol-Myers Squibb

For the treatment of hepatocellular carcinoma.

Tablets: 40mg (1 x 4 ml), 100mg (1 x 10 ml)

Frequently asked questions

Through Email: Please send your order directly to info@onco-connect.com.  We will respond within 24 hours after receiving your mail. We would need details of medicine like name, strength and quantity. You are also required to attach copy of prescription and patient’s Indian Govt. issued identity card (photo with Address) along with email. 

Upon receiving your confirmation, we will raise Pro-Forma Invoice containing details of medicine, price, logistic cost and all other charges applicable. Payment needs to be done in advance.

We will require the following documents to process your order immediately

  • Doctor’s Prescription – Signed and Stamped Scan copy of Doctor’s prescription need to be attached with your order confirmation mail. Doctor’s Registration No is also required on the prescription.
  • Patient’s Identity card – We will require scan copy of Patient’s identity card to process order. Identity card can be Passport copy, Driving License copy, Aadhar card or any Photo ID document.
  • Purchase Order Form – We will send Purchase Order Form through mail once you decide to purchase medicine through us. This need to be filled signed and send us along with other documents as mentioned above

We work with FDA approved suppliers and any medicines that we procure need valid prescription. We need authentic prescription from a practising medical doctor (Registered Medical Practitioner)

  • Doctor prescription: Scan copy of doctor prescription. Prescription should have Doctor Registration Number, signed, dated and stamped. Please send copy of prescription through email. 
  • Patient Identity card: We require scan copy of either Passport, Driving License or Aadhar card or any other Photo ID. 
  • Purchase order Form: We will send Purchase Order Form through mail once you decide to purchase medicine through us. This need to be filled signed and send us along with other documents as mentioned above

Our suppliers source medicine from authorised distributors of the company. We work with European suppliers where strict adherence to values, quality and delivery is maintained. All your medicines would come sealed and will have prescribing information.

Shipment charges depend on quantity, country and product. There are products which require shipment under temperature controlled (between 2-8C) will cost more than products which can be shipped at normal temperature. Shipment Charges includes Logistic cost, documentation and NOC clearance from authority.

  • Step 1: Once Purchase Order is raised with all necessary documentation we would raise a Pro-Forma Invoice containing details of medicine, price, logistic cost and all other charges applicable.
  • Step 2: Online payment needs to be completed using bank details mentioned on the Pro-Forma Invoice. Delivery of medicine will be through courier once we receive money. We provide mail service tracking and would assist in every step forward.